X4 Pharmaceuticals Inc
For the period ended May 1, 2025. Filed May 1, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 1, 2025 · Filed May 1, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Reverse Stock Split
Reverse Stock Split
On April 24, 2025, X4 announced a one-for-thirty reverse stock split of the company’s Common Stock. The reverse stock split took effect at 12:01 a.m. ET on April 28, 2025, and the company’s Common Stock began trading on a split-adjusted basis on The Nasdaq Capital Market as of the opening of trading the same day under a new CUSIP number (98420X202). The reverse split reduced the number of outstanding shares of the company’s Common Stock from approximately 173.6 million shares to approximately 5.8 million shares.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.